Bethany Tesar

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

20h-index5.2kcitations61works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(38), Glycosylation and Glycoproteins Research(13), Immune Response and Inflammation(12), Lymphoma Diagnosis and Treatment(11), T-cell and B-cell Immunology(10)

Publications61 total

Delivery of ATSP-7041 by Minimally Invasive Nasal Depot (MIND) to Target Diffuse Intrinsic Pontine Glioma
Molecular Cancer Therapeutics·2026
A triple-action PROTAC for wild-type p53 cancer therapy
Cell Reports Medicine·2025Open Access
Rare germline variant in NFATC4 associated with familial CLL
Leukemia·2025
Supplementary Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
2023Open Access
Data from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Table 6 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
2023Open Access
Supplementary Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
2023Open Access
Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Table 6 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Data from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia
2023Open Access
Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
2023Open Access
Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence
2022· 20 citedOpen Access
Abstract LB-A20: True small molecule STING agonist generates systemic and potent anti-tumor immunity required for effective cancer immunotherapy
Molecular Cancer Therapeutics·2019
<scp>MYD</scp>88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in <scp>CLL</scp>
British Journal of Haematology·2018· 22 citedOpen Access
Rare Germline Variant in NFATC4 Associated with Familial Chronic Lymphocytic Leukemia
Blood·2017· 1 cited
Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Clinical Cancer Research·2016· 92 citedOpen Access
Discovery of a Series of 5,11-Dihydro-6<i>H</i>-benzo[<i>e</i>]pyrimido[5,4-<i>b</i>][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors
ACS Medicinal Chemistry Letters·2016· 17 citedOpen Access
MYD88 L265P Mutations Influence Clinical Outcome and Identify a Pathway for Targeted Inhibition in Chronic Lymphocytic Leukemia
Blood·2015
page 1 of 4Next →

Frequent Co-authors

Jennifer R. Brown(31), Stacey M. Fernandes(25), Donna Neuberg(22), Lillian Werner(20), Daniel R. Goldstein(14), Arnold S. Freedman(14), Gad Getz(13), Catherine J. Wu(13), Megan Hanna(10), Nathalie Pochet(10), Laura E. MacConaill(10), Alexander R. Vartanov(9), Carrie Sougnez(8), Kevin Hoang(8), Mick Correll(8), Aviv Regev(8), Petar Stojanov(7), Michael S. Lawrence(7), Reina Improgo(7), Stacey Gabriel(6)